EYEGATE PHARMACEUTICALS INC Uncategorized Contracts & Agreements
26 Contracts & Agreements
- First Amendment to Licensed Agreement, dated as of November 5, 2023, between Bayon Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on November 9, 2023)
- Form of Warrant Agency Agreement by and between the Registrant and VStock Transfer, LLC (Filed With SEC on June 1, 2023)
- Form of Class D Common Stock Purchase Warrant (Filed With SEC on June 1, 2023)
- Form of Class C Common Stock Purchase Warrant (Filed With SEC on June 1, 2023)
- Form of Underwriting Agreement between the Registrant and Ladenburg Thalmann & Co. Inc (Filed With SEC on June 1, 2023)
- Form of Inducement Letter (Filed With SEC on November 21, 2022)
- Offer Letter by and between Kiora Pharmaceuticals, Inc. and Melissa Tosca, dated as of August 18, 2022 (Filed With SEC on September 16, 2022)
- Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of August 5, 2021 (Filed With SEC on August 10, 2021)
- Amendment No. 2 to Sub-License Agreement, dated as of February 17, 2016, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Amendment No. 1 to Sub-License Agreement, dated as of September 18, 2015, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Exclusive Sub-License Agreement, dated as of September 12, 2013, by and between Jade Therapeutics, Inc. and Biotime, Inc (Filed With SEC on March 4, 2020)
- Description of Securities (Filed With SEC on March 4, 2020)
- Engagement Letter between EyeGate Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC, dated as of December 30, 2019 (Filed With SEC on December 31, 2019)
- Engagement Letter, dated as March 15, 2018, by and between the Registrant and H.C. Wainwright & Co., LLC (Filed With SEC on April 9, 2018)
- Offer Letter between the Company and Sarah Romano, dated as of January 1, 2018 (Filed With SEC on January 4, 2018)
- 271 Waverly Oaks Road, Suite 108 Waltham, MA 02452 (Filed With SEC on February 6, 2017)
- AT THE MARKET OFFERING AGREEMENT May 24, 2016 (Filed With SEC on May 25, 2016)
- 271 Waverly Oaks Road, Suite 108 Waltham, MA 02452 (Filed With SEC on April 29, 2016)
- EYEGATE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED EMPLOYMENTAGREEMENT (Filed With SEC on March 30, 2016)
- EYEGATEPHARMACEUTICALS, INC. Amendment to Amended and RestatedEmployment Agreement (Filed With SEC on May 15, 2015)
- UNDERWRITINGAGREEMENT between EYEGATEPHARMACEUTICALS, INC. and AEGISCAPITAL CORP., asRepresentative of the Several Underwriters (Filed With SEC on December 24, 2014)
- Form of Representative’s WarrantAgreement (Filed With SEC on August 29, 2014)
- EYEGATE PHARMACEUTICALS, INC. 271 Waverley Oaks Road Suite 108 Waltham, MA 02452 (Filed With SEC on July 30, 2014)
- EYEGATE PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED EMPLOYMENTAGREEMENT (Filed With SEC on July 30, 2014)
- INDEMNIFICATIONAGREEMENT (Filed With SEC on July 30, 2014)
- Hereinafter known as the “OPTIS GROUP” (Filed With SEC on July 30, 2014)